延长重组人α―2b干扰素抗乙肝病毒治疗疗程临床分析.docVIP

延长重组人α―2b干扰素抗乙肝病毒治疗疗程临床分析 　　【摘要】 目的：通过延长重组人α-2b干扰素疗程提高慢性乙肝患者的应答率。方法：选取本院 　　2009年12月-2013年12月收治的HBeAg阳性慢性乙型病毒性肝炎患者100例作为研究对象，采用随机数字表法将所选患者分为两组，观察组45例，对照组55例。观察组给予重组人α-2b干扰素600万单位， 　　皮下注射，隔日1次，疗程为18个月；而对照组疗程为12个月。对两组患者进行随访，治疗 　　6个月、治疗12个月、治疗结束时、停药随访6个月、停药随访12个月、停药随访18个月时，观察两组患者的肝功能复常、HBeAg转阴、HBeAg/HBeAb转换、HBVDNA转阴等情况。结果：治疗结束时，观察组肝功能复常率优于对照组，比较差异有统计学意义（P0.05）。随访6、12、18个月，观察组的肝功能复常率、HBVDNA转阴率均优于对照组，比较差异均有统计学意义（P0.05）；随访12、18个月，观察组HBeAg转阴率、HBeAg/HBeAb转换率均高于对照组，比较差异均有统计学意义（P0.05）。结论：延长重组人α-2b干扰素治疗HBeAg阳性慢性乙型病毒性肝炎疗程能提高患者的应答率，减少复发率，使患者达到更长期的稳定，延缓病情的进展，减少肝硬化和肝癌的发生。 　　【关键词】 重组人α-2b干扰素； HBeAg阳性慢性乙型病毒性肝炎； 应答率 　　Clinical Analysis of Prolonged Recombinant Interferon α-2b Treatment against Hepatitis B Virus/LIU Hua-mei.//Medical Innovation of China，2016，13（10）：019-022 　　【Abstract】 Objective：To improve the response rates of patients with chronic hepatitis B by prolonged treatment of recombinant interferon α-2b.Method：A total of 100 patients with HBeAg-positive chronic hepatitis B in our hospital from December 2009 to December 2013 were selected as the research objects.They were randomly divided into the observation group（45 cases） and the control group（55 cases）.The observation group was given subcutaneous injection of 6 million units recombinant interferon α-2b once every other day for 18 months，the control group was given subcutaneous injection of 6 million units recombinant interferon α-2b once every other day for 12 months.All subjects were followed up after the end of treatment.The situation of the recovery of liver function，HBeAg loss，HBeAg/HBeAb seroconversion and clearance of HBVDNA were observed and compared between the two groups 6，12 months after treatment，at the end of the treatment and follow up for 6，12，18 months.Result：At the end of the treatment，the recovery rate of liver function in the observation group was better than that in the control group，the difference was statistically significant（P0.05）.After following up 6，12，18 months，the recovery rates of liver